Xenon Pharmaceuticals Inc.
XENE evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for XENE—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · XENE
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for neurological disorders, with its lead product candidate azetukalner in Phase 3 trials for epilepsy and major depressive disorder, and has no approved products or product revenue as of mid-2026.
Key risk: No approved products or revenue
BioSniper Score
Based on 6 of 6 signals
Market Cap
$5.81B
Cash Runway
28.1 moLead Asset
azetukalner (Phase 3)Next Catalyst
Phase3_Topline · Oct 1, 2026Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 13 clinical trials · 8 catalysts for Xenon Pharmaceuticals Inc..
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for neurological disorders, with its lead product candidate azetukalner in Phase 3 trials for epilepsy and major depressive disorder, and has no approved products or product revenue as of mid-2026.
- Lead candidate azetukalner is in multiple Phase 3 trials for epilepsy and major depressive disorder, with topline data readouts expected from late 2026 through 2029 [sec_mda · as of 2026-08-06].
- Cash and equivalents were $119.5M as of June 30, 2026, with management expecting existing resources to fund operations for at least the next 12 months [sec_mda · as of 2026-08-06].
- Net loss for the six months ended June 30, 2026 was $110.7M, and accumulated deficit reached $1,458.4M as of that date [sec_mda · as of 2026-08-06].
- The company has no approved products and has not generated any product sales revenue; revenue in prior periods came solely from collaboration agreements [sec_mda · as of 2026-08-06].
- A Phase 1b study of NBI-921355 (Nav1.2/Nav1.6 inhibitor) in collaboration with Neurocrine Biosciences is ongoing, with data expected in 2027 [sec_mda · as of 2026-08-06].
What works
- Xenon has a deep pipeline with azetukalner in multiple Phase 3 trials across epilepsy and major depressive disorder, providing multiple shots on goal for potential regulatory approval [sec_mda · as of 2026-08-06].
- The company has a collaboration with Neurocrine Biosciences for NBI-921355, which could provide additional development resources and validation [sec_mda · as of 2026-08-06].
- Management expects existing cash to fund operations for at least the next 12 months, suggesting a manageable near-term liquidity runway [sec_mda · as of 2026-08-06].
What to weigh
- Xenon has a significant accumulated deficit of $1,458.4M as of June 30, 2026, with no approved products or product revenue, and expects to continue incurring net losses for the foreseeable future [sec_mda · as of 2026-08-06].
- The company is entirely dependent on the success of its clinical-stage candidates, particularly azetukalner, and any clinical or regulatory setbacks could materially impact its viability [sec_mda · as of 2026-08-06].
- Operating expenses are expected to increase substantially as the company prepares for potential commercial launch and advances additional programs, which may require significant additional capital beyond current cash [sec_mda · as of 2026-08-06].
From the filings
Quoted directly from source documents.
Xenon has no approved products and has not generated product sales revenue.
“To date, we have not had any products approved for sale and have not generated any revenue from product sales.”
SEC MD&A · May 7, 2026
Accumulated deficit as of June 30, 2026 was $1,458.4 million.
“As of June 30, 2026, we had an accumulated deficit of $1,458.4 million.”
SEC MD&A · August 6, 2026
Management expects existing cash to fund operations for at least the next 12 months.
“we expect that our existing cash and cash equivalents and marketable securities as of the date of this report, will enable us to fund our operating expenses and capital expenditure requirements for at least the next 12 months.”
SEC MD&A · August 6, 2026
Phase 1b data for NBI-921355 are expected in 2027.
“Data from the Phase 1b study are expected in 2027.”
SEC MD&A · August 6, 2026
Catalyst timeline
- 2026-10-01 · Phase3_Topline — Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate Azetukalner i — First Phase 3 topline readout for azetukalner in an epilepsy indication; results will be a key value driver.
- 2026-12-01 · Phase3_Topline — Phase 3 Topline: A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, To — Second Phase 3 topline readout for azetukalner in epilepsy; will inform the registration package.
- 2027-03-01 · Phase3_Topline · azetukalner — Phase 3 Topline: A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of Azetukalner in Maj — Phase 3 topline data for azetukalner in major depressive disorder; first readout in a new indication.
- 2027-06-01 · Phase3_Topline — Phase 3 Topline: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Study to Evaluate the Safety, T — Additional Phase 3 topline readout for azetukalner in epilepsy; further data to support potential approval.
- 2028-08-01 · Phase3_Topline — Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate Azetukalner i — Later-stage Phase 3 topline readout for azetukalner in epilepsy; may support label expansion.
- 2029-08-01 · Phase3_Topline · azetukalner — Phase 3 Topline: A Multicenter, Long-term, Open-Label, Safety, Tolerability, and Efficacy Study of Azetukalner in Bip — Phase 3 topline data for azetukalner in bipolar disorder; potential new indication.
- 2033-06-01 · Phase3_Topline · xen1101 — Phase 3 Topline: A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of XEN1101 in Subject — Long-term safety and efficacy data for XEN1101 (azetukalner) in a chronic treatment setting.
Risks & what to watch (4)›
Key risks
- No approved products or revenue — Xenon has no products approved for sale and has never generated product revenue; future revenue depends entirely on clinical success and regulatory approval [sec_mda · as of 2026-08-06].
- Substantial accumulated deficit — Accumulated deficit of $1,458.4M as of June 30, 2026, with net losses expected to continue for the foreseeable future [sec_mda · as of 2026-08-06].
- Dependence on azetukalner success — The company's near-term prospects hinge on azetukalner Phase 3 results; failure could materially impair the business [sec_mda · as of 2026-08-06].
- Need for additional capital — Operating expenses are expected to rise substantially, and the company may require additional funding beyond current cash to complete development and commercialization [sec_mda · as of 2026-08-06].
What to watch
- Phase 3 topline data for azetukalner in epilepsy and major depressive disorder, with multiple readouts expected from late 2026 through 2029 [sec_mda · as of 2026-08-06].
- Phase 1b data for NBI-921355 (Nav1.2/Nav1.6 inhibitor) expected in 2027 [sec_mda · as of 2026-08-06].
- Cash burn rate and any future financing activities, given the company's net losses and rising expenses [sec_mda · as of 2026-08-06].
- Regulatory and commercial preparation activities for azetukalner, which will significantly increase operating costs [sec_mda · as of 2026-08-06].
Sources: SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Xenon Pharmaceuticals Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Xenon Pharmaceuticals Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
28.1 months
D/E 0.04 · 0% dilution
Lead: Phase 3
2 candidates
8 upcoming, next in ~32d
0 buys · 18 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
291
Total value held
$5.52B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 10,818,491 | $629.1M |
| janus henderson group plc | 8,351,964 | $485.7M |
| blackrock, inc. | 5,640,118 | $328.0M |
| wellington management group llp | 4,829,641 | $280.8M |
| driehaus capital management llc | 4,491,653 | $261.2M |
| polar capital holdings plc | 4,405,312 | $256.2M |
| citadel advisors llc | 2,886,390 | $167.8M |
| state street corp | 1,720,533 | $100.0M |
| susquehanna international group, llp | 1,695,037 | $98.6M |
| affinity asset advisors, llc | 1,675,000 | $97.4M |
Showing top 10 of 291 institutional holders of Xenon Pharmaceuticals Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 5.0%
- Days to cover
- 4.1
- Shares short
- 4,854,352
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
XENE short interestGovernance
Frequently asked questions
What is the AI investment thesis for Xenon Pharmaceuticals Inc.?
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for neurological disorders, with its lead product candidate azetukalner in Phase 3 trials for epilepsy and major depressive disorder, and has no approved products or product revenue as of mid-2026.
What is Xenon Pharmaceuticals Inc.'s lead drug candidate?
Xenon Pharmaceuticals Inc.'s most advanced tracked candidate is azetukalner (Phase 3) for Major Depressive Disorder; Bipolar Depression; Bipolar Disorder.
What is Xenon Pharmaceuticals Inc.'s next catalyst?
Xenon Pharmaceuticals Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate Azetukalner i" — expected October 1, 2026.
Who is the CEO of Xenon Pharmaceuticals Inc.?
Mr. Ian C. Mortimer C.M.A., CPA, M.B.A. is the chief executive officer of Xenon Pharmaceuticals Inc. (XENE).
Where is Xenon Pharmaceuticals Inc. headquartered?
Xenon Pharmaceuticals Inc. (XENE) is headquartered in Burnaby, BC, Canada.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.